Kei­th Dion­ne's Cas­ma lines up a $50M ven­ture round to con­tin­ue the pre­clin­i­cal work on a cel­lu­lar re­cy­cling pro­gram

Two years af­ter launch­ing out of Third Rock’s in­cu­ba­tor, Cas­ma Ther­a­peu­tics has land­ed a $50 mil­lion Se­ries B for pre­clin­i­cal de­vel­op­ment of its mus­cu­lar dy­s­tro­phy and Au­tophagy De­grad­er Plat­form (ADP) pro­grams.

Cas­ma kicked off in 2018 with a $58.5 mil­lion Se­ries A and a staff of ex­perts in au­tophagy, the cell’s “garbage dis­pos­al.” The biotech’s TRPML1 ag­o­nist pro­gram for mus­cu­lar dy­s­tro­phy is ex­pect­ed to hit the clin­ic in 2022, ac­cord­ing to CEO Kei­th Dionne, and the ADP pro­gram is about a year be­hind that.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER